Zydus Pharmaceuticals Inc.: Poised for the Future

Published Online: Wednesday, August 29, 2012
Follow Pharmacy_Times:

Zydus Pharmaceuticals (USA) Inc., located in Pennington, New Jersey, is looking forward to its future in the US pharmaceutical market. Since its first commercial launch in August 2005, it has grown steadily over the past 7 years and now offers more than 250 SKUs to the US market. For the 7th straight year, IMS Health has recognized Zydus as one of the fastest growing pharmaceutical companies by total prescriptions dispensed.

This is an exciting time for Zydus Pharmaceuticals as the company continues to expand its portfolio to offer new dosage forms and enter different franchises within the US pharmaceutical market. In the near future, Zydus hopes to introduce nasal sprays for the first time in the United States. Zydus is also aggressively pursuing other franchises, such as dermatologic and oncology products, as well as metered dose inhalers. With the purchase of Nesher Pharmaceuticals in St. Louis, Missouri, Zydus has a footprint in the United States and will be able to enter the controlled substances sector. The company has worked extremely hard to put together a rich product pipeline for the future.

Zydus Pharmaceuticals’ parent company, Zydus Cadila, is India’s 5th largest pharmaceutical company and has experienced tremendous growth over the past several years. It is a global pharmaceutical company with business operations in more than 50 countries, including the United States, Europe, Japan, Spain, Brazil, and Mexico. With more than 14,000 employees across 26 countries, India’s largest finished dosage plant under one roof, 2 FDA-approved API sites, and the ability to manufacture a wide variety of dosage forms, Zydus Cadila is more than ready to support the rapidly growing US pharmaceutical market. With the FDA approval of its Baddi plant and its newest manufacturing plant completed, Zydus will soon have a pill and capsule capacity exceeding 20 billion annually.

With the strength and worldwide reputation of Zydus Cadila supporting the US division, Zydus Pharmaceuticals is looking forward to continuing its growth in the US marketplace. As the company focuses its efforts on more challenging and rewarding opportunities, including several first-to-file and 505B2 opportunities, it looks forward to great success as the company expands. To date, Zydus has filed 107 drug master files (DMFs), received 67 Abbreviated New Drug Application (ANDA) final and tentative approvals, and has 75 ANDAs pending approval with the FDA. Look for some exciting announcements from Zydus over the next 12 months, as they are truly “poised for the future.”

You can visit Zydus Pharmaceuticals (USA) Inc. at NACDS Pharmacy and Technology at booth 1404 or learn more about the company through its website at www.zydususa.com.

Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Mylan Inc. today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times